{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:28:22Z","timestamp":1780320502023,"version":"3.54.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T00:00:00Z","timestamp":1515715200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s40256-017-0252-1","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T06:02:05Z","timestamp":1515736925000},"page":"195-204","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Ivabradine for the Treatment of Postural Orthostatic Tachycardia Syndrome: A Systematic Review"],"prefix":"10.1007","volume":"18","author":[{"given":"Megan E.","family":"Gee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia K.","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie N.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily J. A.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,12]]},"reference":[{"key":"252_CR1","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.autneu.2013.06.008","volume":"177","author":"SR Raj","year":"2013","unstructured":"Raj SR. Highlights in clinical autonomic neurosciences: treatment insights for postural tachycardia syndrome and inappropriate sinus tachycardia. Auton Neurosci. 2013;177:72\u20133.","journal-title":"Auton Neurosci"},{"key":"252_CR2","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3399\/bjgp12X648963","volume":"62","author":"L Kavi","year":"2012","unstructured":"Kavi L, Gammage MD, Grubb BP, Karabin BL. Postural tachycardia syndrome: multiple symptoms, but easily missed. Br J Gen Pract. 2012;62:286\u20137.","journal-title":"Br J Gen Pract"},{"key":"252_CR3","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1016\/j.hrthm.2015.03.029","volume":"12","author":"RS Sheldon","year":"2015","unstructured":"Sheldon RS, Grubb BP, Olshansky B, et al. Heart Rhythm Society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm. 2015;12:e41\u201363.","journal-title":"Heart Rhythm"},{"key":"252_CR4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/europace\/eun324","volume":"11","author":"S Carew","year":"2009","unstructured":"Carew S, Connor MO, Cooke J, et al. A review of postural orthostatic tachycardia syndrome. Europace. 2009;11:18\u201325.","journal-title":"Europace"},{"key":"252_CR5","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1161\/CIRCULATIONAHA.112.144501","volume":"127","author":"SR Raj","year":"2013","unstructured":"Raj SR. Postural tachycardia syndrome (POTS). Circulation. 2013;127:2336\u201342.","journal-title":"Circulation"},{"key":"252_CR6","unstructured":"CORLANOR (ivabradine). US package insert. Thousand Oaks, CA: Amgen Inc; 2015. \n                    http:\/\/pi.amgen.com\/~\/media\/amgen\/repositorysites\/pi-amgen-com\/corlanor\/corlanor_pi_hcp.pdf\n                    \n                  . Accessed 30 Oct 2017."},{"key":"252_CR7","unstructured":"PROCORALAN (ivabradine).\u00a0European Medicines Agency Report summary for the public. 2005. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/000597\/WC500043585.pdf\n                    \n                  . Accessed 30 Oct 2017."},{"key":"252_CR8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1517\/14656566.2011.548321","volume":"12","author":"G Riccioni","year":"2011","unstructured":"Riccioni G. Ivabradine: recent and potential applications in clinical practice. Expert Opin Pharmacother. 2011;12:443\u201350.","journal-title":"Expert Opin Pharmacother"},{"key":"252_CR9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40256-016-0178-z","volume":"16","author":"CS Oliphant","year":"2016","unstructured":"Oliphant CS, Owens RE, Bolorunduro OB, Jha SK. Ivabradine: a review of labeled and off-label uses. Am J of Cardiovasc Drugs. 2016;16:337\u201347.","journal-title":"Am J of Cardiovasc Drugs"},{"key":"252_CR10","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1161\/HYPERTENSIONAHA.115.06091","volume":"66","author":"JG Dillinger","year":"2015","unstructured":"Dillinger JG, Maher V, Vitale C, et al. Impact of ivabradine on central aortic blood pressure and myocardial perfusion in patients with stable coronary artery disease. Hypertension. 2015;66:1138\u201344.","journal-title":"Hypertension"},{"key":"252_CR11","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/europace\/euq390","volume":"13","author":"C McDonald","year":"2011","unstructured":"McDonald C, Frith J, Newton JL. Single centre experience of ivabradine in postural orthostatic tachycardia syndrome. Europace. 2011;13:427\u201330.","journal-title":"Europace"},{"key":"252_CR12","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264\u20139.","journal-title":"Ann Intern Med"},{"key":"252_CR13","doi-asserted-by":"publisher","first-page":"e0028","DOI":"10.5041\/RMMJ.10213","volume":"6","author":"M Barzilai","year":"2015","unstructured":"Barzilai M, Jacob G. The effect of ivabradine on the heart rate and sympathovagal balance in postural tachycardia syndrome patients. Rambam Maimonides Med J. 2015;6:e0028.","journal-title":"Rambam Maimonides Med J"},{"key":"252_CR14","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/europace\/eut226","volume":"16","author":"R Sutton","year":"2014","unstructured":"Sutton R, Salukhe TV, Franzen-Mcmanus AC, Collins A, Lim PB, Francis DP. Ivabradine in treatment of sinus tachycardia mediated vasovagal syncope. Europace. 2014;16:284\u20138.","journal-title":"Europace"},{"key":"252_CR15","doi-asserted-by":"publisher","unstructured":"Delle Donne G, Noguer FR, Till J et al. Ivabradine in postural orthostatic tachycardia syndrome: preliminary experience in children. Am J Cardiovasc Drugs. \n                    https:\/\/doi.org\/10.1007\/s40256-017-0248-x\n                    \n                  .","DOI":"10.1007\/s40256-017-0248-x"},{"key":"252_CR16","doi-asserted-by":"publisher","unstructured":"Ruzieh M, Sirianni N, Ammari Z, et al. Ivabradine in the treatment of postural tachycardia syndrome (POTS), a single center experience. Pacing Clin Electrophysiol. \n                    https:\/\/doi.org\/10.1111\/pace.13182\n                    \n                  .","DOI":"10.1111\/pace.13182"},{"key":"252_CR17","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.jdiacomp.2015.02.003","volume":"29","author":"C Meyer","year":"2015","unstructured":"Meyer C, M\u00fchlsteff J, Drexel T, et al. POTS following traumatic stress: interacting central and intracardiac neural control? J Diabetes Complicat. 2015;29:459\u201361.","journal-title":"J Diabetes Complicat"},{"key":"252_CR18","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1111\/j.1540-8167.2011.02078.x","volume":"22","author":"Y Nakatani","year":"2011","unstructured":"Nakatani Y, Mizumaki K, Nishida K, Inoue H. Atrioventricular node ablation and pacemaker implantation for recurrent syncope in a patient with postural tachycardia syndrome (POTS). J Cardiovasc Electrophysiol. 2011;22:1284\u20137.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"252_CR19","first-page":"285","volume":"38","author":"F Aliyev","year":"2010","unstructured":"Aliyev F, \u00c7eliker C, T\u00fcrko\u011flu C, Uzunhasan I. Successful use of ivabradine in a case of exaggerated autonomic dysfunction. Turk Kardiyol Dern Ars. 2010;38:285\u20139.","journal-title":"Turk Kardiyol Dern Ars"},{"key":"252_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1540-8159.2009.02186.x","volume":"32","author":"S Khan","year":"2009","unstructured":"Khan S, Hamid S, Rinaldi C. Treatment of inappropriate sinus tachycardia with ivabradine in a patient with postural orthostatic tachycardia syndrome and a dual chamber pacemaker. Pac Clin Electrophysiol. 2009;32:131\u20133.","journal-title":"Pac Clin Electrophysiol"},{"key":"252_CR21","first-page":"8542158","volume":"2016","author":"F Oztunc","year":"2016","unstructured":"Oztunc F, Ugan Atik S, Dedeoglu R, Erbek Alp F, Gokalp S. Cooccurrence of postural orthostatic tachycardia syndrome with two different clinical entities. Case Rep Pediatr. 2016;2016:8542158.","journal-title":"Case Rep Pediatr"},{"key":"252_CR22","doi-asserted-by":"publisher","first-page":"166","DOI":"10.2174\/1874192401004010166","volume":"4","author":"AS Hersi","year":"2010","unstructured":"Hersi AS. Potentially new indication of ivabradine: treatment of a patient with postural orthostatic tachycardia syndrome. Open Cardiovasc Med J. 2010;4:166\u20137.","journal-title":"Open Cardiovasc Med J"},{"key":"252_CR23","first-page":"745","volume":"2","author":"S Jamil-Copley","year":"2010","unstructured":"Jamil-Copley S, Nagarajan DV, Baig MK. Use of ivabradine in postural orthostatic tachycardia syndrome. J Atr Fibrillat. 2010;2:745\u20136.","journal-title":"J Atr Fibrillat"},{"key":"252_CR24","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1093\/europace\/eum235","volume":"9","author":"V Ewan","year":"2007","unstructured":"Ewan V, Norton M, Newton JL. Symptom improvement in postural orthostatic tachycardia syndrome with the sinus node blocker ivabradine. Europace. 2007;9:1202.","journal-title":"Europace"},{"key":"252_CR25","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/S0025-6196(11)61027-6","volume":"82","author":"MJ Thieben","year":"2007","unstructured":"Thieben MJ, Sandroni P, Sletten DM, et al. Postural orthostatic tachycardia syndrome: the Mayo Clinic experience. Mayo Clin Proc. 2007;82:308\u201313.","journal-title":"Mayo Clin Proc"},{"key":"252_CR26","doi-asserted-by":"publisher","first-page":"13592","DOI":"10.3390\/molecules171113592","volume":"17","author":"G Riccioni","year":"2012","unstructured":"Riccioni G. Ivabradine: an intelligent drug for the treatment of ischemic heart disease. Molecules. 2012;17:13592\u2013604.","journal-title":"Molecules"},{"key":"252_CR27","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","volume":"376","author":"K Swedberg","year":"2010","unstructured":"Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875\u201385.","journal-title":"Lancet"},{"key":"252_CR28","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","volume":"372","author":"K Fox","year":"2008","unstructured":"Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807\u201316.","journal-title":"Lancet"},{"key":"252_CR29","unstructured":"Ivabradine. In: Lexi-Drugs Online. Hudson, OH: Lexi-Comp, Inc. Available at: \n                    http:\/\/online.lexi.com\n                    \n                  . Accessed October 10, 2017."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-017-0252-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-017-0252-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-017-0252-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,12]],"date-time":"2019-01-12T01:48:05Z","timestamp":1547257685000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-017-0252-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,12]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["252"],"URL":"https:\/\/doi.org\/10.1007\/s40256-017-0252-1","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,12]]},"assertion":[{"value":"12 January 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Megan E. Gee, Alicia K. Watkins, Jamie N. Brown and Emily J. A. Young declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"No external funding was used in the preparation of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}